Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis
Authors:
- Ling-Na NiLNLing-Na Ni
- Gui-Feng ShengGSGui-Feng Sheng
- Hong-Lei SongHSHong-Lei Song
- Jian-Zhong XuJXJian-Zhong Xu
- Yang LingYLYang Ling
- 1 July 2013
- journal article
- research article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 57 (3) , 209-214
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reportsAnnals of Oncology, 2010
- Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B‐cell lymphoma patients who are HBsAg‐negative/ HBcAb‐positive: a multicenter retrospective studyEuropean Journal of Haematology, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenanceHaematologica, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Hepatitis B Virus InfectionNew England Journal of Medicine, 2008
- Preventing hepatitis B virus reactivation following immunosuppressive therapyInternal Medicine Journal, 2008
- Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapyHaematologica, 2008
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatology International, 2008
- Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphomaBMC Cancer, 2008